非小细胞肺癌脑转移的靶向药物治疗研究进展

被引：10

作者：

宋昆 ^{[1
]}

吕一正 ^{[2
]}

徐铭 ^{[2
]}

徐宏治 ^{[1
]}

机构：

[1] 复旦大学附属华山医院神经外科

[2] 复旦大学附属华山医院麻醉科

来源：

中国临床神经科学 | 2019年 / 27卷 / 05期

关键词：

非小细胞肺癌; 脑转移; 靶向药物治疗;

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学]; R734.2 [肺肿瘤];

学科分类号：

100117 [系统生物医学]; 100214 [肿瘤学];

摘要：

中枢神经系统转移肿瘤绝大多数起源于肺癌,其中非小细胞肺癌发病率占80%左右。非小细胞肺癌早期患者即有10%进展为颅内转移,手术治疗及放疗是脑转移的经典治疗方法,但治疗后易复发。由于血脑屏障的存在,常规化疗药物难以在转移灶内发挥疗效,总体预后不佳。近年来,靶向药物如表皮生长因子受体酪氨酸激酶抑制剂、间变性淋巴瘤激酶抑制剂在脑转移患者中表现出了较好的疗效,已成为非小细胞肺癌脑转移患者的可选治疗方案。文中就非小细胞肺癌脑转移的靶向药物治疗的进展进行综述。

引用

页码：585 / 591

页数：7

共 24 条

[1]

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study [J].

Solomon, Benjamin J. ;

Besse, Benjamin ;

Bauer, Todd M. ;

Felip, Enriqueta ;

Soo, Ross A. ;

Camidge, D. Ross ;

Chiari, Rita ;

Bearz, Alessandra ;

Lin, Chia-Chi ;

Gadgeel, Shirish M. ;

Riely, Gregory J. ;

Tan, Eng Huat ;

Seto, Takashi ;

James, Leonard P. ;

Clancy, Jill S. ;

Abbattista, Antonello ;

Martini, Jean-Francois ;

Chen, Joseph ;

Peltz, Gerson ;

Thurm, Holger ;

Ou, Sai-Hong Ignatius ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2018, 19 (12) :1654-1667

[2]

Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer [J].

Li, Xue ;

Wang, Yingchun ;

Wang, Jia ;

Zhang, Tianwei ;

Zheng, Li ;

Yang, Zhenfan ;

Xing, Ligang ;

Yu, Jinming .

INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (01) :212-224

[3]

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial [J].

Yang, Jin-Ji ;

Zhou, Caicun ;

Huang, Yisheng ;

Feng, Jifeng ;

Lu, Sun ;

Song, Yong ;

Huang, Cheng ;

Wu, Gang ;

Zhang, Li ;

Cheng, Ying ;

Hu, Chengping ;

Chen, Gongyan ;

Zhang, Li ;

Liu, Xiaoqing ;

Yan, Hong Hong ;

Tan, Fen Lai ;

Zhong, Wenzhao ;

Wu, Yi-Long .

LANCET RESPIRATORY MEDICINE, 2017, 5 (09) :707-716

[4]

Pulsatile Erlotinib in EGFR-Positive Non–Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.[J].Joan How;Janelle Mann;Andrew N. Laczniak;Maria Q. Baggstrom.Clinical Lung Cancer.2017, 4

[5]

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity [J].

Ballard, Peter ;

Yates, James W. T. ;

Yang, Zhenfan ;

Kim, Dong-Wan ;

Yang, James Chih-Hsin ;

Cantarini, Mireille ;

Pickup, Kathryn ;

Jordan, Angela ;

Hickey, Mike ;

Grist, Matthew ;

Box, Matthew ;

Johnstrom, Peter ;

Varnas, Katarina ;

Malmquist, Jonas ;

Thress, Kenneth S. ;

Janne, Pasi A. ;

Cross, Darren .

CLINICAL CANCER RESEARCH, 2016, 22 (20) :5130-5140

[6]

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.[J].Chee-Seng Tan;Byoung-Chul Cho;Ross A. Soo.Lung Cancer.2016,

[7]

CSF Concentration of Crizotinib in Two ALK -Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.[J].Giulio Metro;Gianluigi Lunardi;Piero Floridi;Jennifer P. Pascali;Luca Marcomigni;Rita Chiari;Vienna Ludovini;Lucio Crinò;Stefania Gori.Journal of Thoracic Oncology.2015, 5

[8]

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers [J].

Rangachari, Deepa ;

Yamaguchi, Norihiro ;

VanderLaan, Paul A. ;

Folch, Erik ;

Mahadevan, Anand ;

Floyd, Scott R. ;

Uhlmann, Erik J. ;

Wong, Eric T. ;

Dahlberg, Suzanne E. ;

Huberman, Mark S. ;

Costa, Daniel B. .

LUNG CANCER, 2015, 88 (01) :108-111

[9]

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease.[J].Petra Hoffknecht;Amanda Tufman;Thomas Wehler;Theo Pelzer;Rainer Wiewrodt;Martin Schütz;Monika Serke;Jan Stöhlmacher-Williams;Angela Märten;Rudolf Maria Huber;Nicolas J. Dickgreber.Journal of Thoracic Oncology.2015, 1

[10]

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases [J].

Kodama, Tatsushi ;

Hasegawa, Masami ;

Takanashi, Kenji ;

Sakurai, Yuji ;

Kondoh, Osamu ;

Sakamoto, Hiroshi .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) :1023-1028

← 1 2 3 →